Pharmaceuticals - Indian - Formulations
28 companies listed on NSE in this sector
India business grew 12% YoY to INR 432 Cr in Q2 FY26, outperforming the Indian Pharmaceutical Market (IPM) growth of 8% by 32%. Asia business grew 5% YoY to INR 310 Cr in Q2 FY26, ...
The company operates in a single segment of Drugs & Chemicals, which achieved a standalone total income of INR 13,575.71 Lacs in FY 2024-25, representing a growth of 9.82% compared...
In FY2025, the OTC segment grew 5.41% to INR 290.03 Cr, the Comfy segment grew 17.77% to INR 123.96 Cr, and the Beverages segment declined 8.88% to INR 36.43 Cr. For H1 FY2026, tot...
The company operates in a single segment: pharmaceutical formulations. Total revenue for FY 2024-25 was INR 145.86 Cr. For the half-year ended September 30, 2025, revenue was INR 7...
Total turnover decreased by 16.82% to INR 3370.74 lacs in FY25 compared to INR 4052.50 lacs in FY24. The Pharma Unit revenue fell 4.33% to INR 2666.03 Lacs, while the Chemicals Uni...
Consolidated revenue from operations grew by 5.91% YoY to INR 846.22 Cr in FY25, driven by a portfolio of 250+ branded formulations across 20+ therapeutic segments. Standalone reve...
Total consolidated revenue grew 15.5% YoY to INR 2,034 Cr in FY25. Revenue from operations increased 14.4% to INR 1,937.47 Cr. The US front-end entity generated initial revenue of ...
Domestic Branded Formulations (DBF) grew 10% YoY in Q2 FY26 to INR 708 Cr and 11% in H1 FY26 to INR 1,410 Cr. The International Business revenue was INR 83 Cr in Q2 FY26, a slight ...
Consolidated revenue grew 6% YoY to INR 14,869 million in Q2 FY26. The US segment grew 8% YoY to INR 8,005 million. Other regulated markets (Europe, Canada, Australia, NZ) grew 18%...
Standalone divisional product sales for Q2 FY26 stood at INR 64 Cr, a 12% decline YoY. H1 FY26 sales were INR 128 Cr, down 13% YoY. Consolidated Revenue from Operations for FY25 wa...
Not disclosed in available documents.
Not disclosed in available documents. However, Profit Before Tax (PBT) for H1 FY26 stood at INR 3.65 Cr, which on an annualized basis (INR 7.30 Cr) represents a 19.05% increase ove...
Total revenue grew 66% YoY to INR 190 Cr in Q2 FY26. The product segment grew approximately 78% YoY, while the services segment contributed 50% of the total revenue during the quar...
Total income grew 14.23% YoY to INR 101.28 Cr in H1 FY26 compared to INR 88.66 Cr in H1 FY25. Growth was primarily driven by the parenteral range (injectables) and increasing tract...
Total Income for FY25 reached INR 645.71 Cr, representing a 5% growth compared to FY24. The 5-year CAGR for revenue stands at 10.26%. The business mix is split between Domestic Sal...
The US and North America segment grew 28.8% YoY in H1 FY26, reaching INR 714.8 Cr. The OTC segment overall has shown significant growth, crossing the INR 2,000 Cr revenue mark in F...
Total revenue from operations grew 14.11% YoY, reaching INR 25.27 Cr in FY24 compared to INR 22.15 Cr in FY23. While specific percentage splits for generic dosage versus the new co...
The company achieved a 28% YoY growth in operating income, reaching INR 179.3 Cr in FY24 compared to INR 140.8 Cr in FY23. Growth is primarily driven by the core formulations segme...
Revenue grew 25.8% YoY to INR 10,391.5 Lacs in FY25. Segment performance in FY25: Tablets reached INR 67 Cr (up 34% from INR 50 Cr), ORS reached INR 16 Cr (up 77.7% from INR 9 Cr),...
In H1 FY26, the CDMO segment grew 72% YoY to INR 667 Cr, contributing 64% of total revenue. The CRO segment grew 28% YoY to INR 367 Cr, contributing 36% of total revenue. For the f...
Standalone revenue reached INR 88.35 crores in H1 FY26, representing a 17% year-on-year growth. The company is targeting a trajectory of INR 300 crores by FY27 and INR 500 crores w...
Regulated Markets grew 86.9% YoY to INR 106.9 Cr in Q2 FY26; Emerging Markets declined 13.4% YoY to INR 31.7 Cr; Branded Generics grew 1337.3% YoY to INR 11.9 Cr; API segment decli...
Consolidated revenue grew 7% YoY to INR 372 Cr in Q2 FY26 and 8% YoY to INR 700 Cr in H1 FY26. Segmental growth for H1 FY26: Non-captive API grew 19% YoY (INR 205 Cr in Q2), Formul...
Pharmaceuticals Drugs & Formulations revenue grew 30.5% YoY to INR 246.98 Cr in H1 FY26. Trading of Commodities revenue fell 72.7% to INR 1.05 Cr. Renting of Property revenue decre...
Consolidated revenues grew 7% to INR 11,516 Cr in FY25. In Q2 FY26, India business grew 12% to INR 1,820 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%. US b...
Consolidated revenue grew 7.72% YoY to ā¹647.89 Cr in FY25, while standalone revenue grew 11.17% to ā¹639.46 Cr. Growth was driven by critical care, anti-infectives, and oncology div...
In H1 FY26, the Generic Formulation CDMO vertical grew 18% YoY, Trade Generics & Institutional grew 25% YoY, and the Exports vertical grew 23% YoY. For Q2 FY26, these segments grew...
The company operates in a single primary business segment (Pharmaceuticals), making segment-wise growth reporting not applicable; however, revenue is described as moderate with a h...